AU2002363800A1 - Therapeutic agent composition and method of use - Google Patents

Therapeutic agent composition and method of use

Info

Publication number
AU2002363800A1
AU2002363800A1 AU2002363800A AU2002363800A AU2002363800A1 AU 2002363800 A1 AU2002363800 A1 AU 2002363800A1 AU 2002363800 A AU2002363800 A AU 2002363800A AU 2002363800 A AU2002363800 A AU 2002363800A AU 2002363800 A1 AU2002363800 A1 AU 2002363800A1
Authority
AU
Australia
Prior art keywords
therapeutic agent
agent composition
composition
therapeutic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002363800A
Inventor
Loi Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002363800A1 publication Critical patent/AU2002363800A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2002363800A 2001-11-13 2002-11-12 Therapeutic agent composition and method of use Abandoned AU2002363800A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ51543201 2001-11-13
NZ515432 2001-11-13
US40590902P 2002-08-26 2002-08-26
US60/405,909 2002-08-26
PCT/US2002/036639 WO2003041655A2 (en) 2001-11-13 2002-11-12 Therapeutic agent composition and method of use

Publications (1)

Publication Number Publication Date
AU2002363800A1 true AU2002363800A1 (en) 2003-05-26

Family

ID=26652293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002363800A Abandoned AU2002363800A1 (en) 2001-11-13 2002-11-12 Therapeutic agent composition and method of use

Country Status (3)

Country Link
AU (1) AU2002363800A1 (en)
CA (1) CA2466701C (en)
WO (1) WO2003041655A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
DK1664050T3 (en) 2003-09-03 2016-03-07 Neuren Pharmaceuticals Ltd Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
US8791117B2 (en) 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
RU2355413C1 (en) * 2007-12-06 2009-05-20 Закрытое Акционерное Общество "Биоген Технолоджиз" Pharmaceutical preparation for treating demyelinating diseases of nervous system, preparation favouring recovery of myelin sheath of nerve fibre, and method of treating demyelinating diseases of nervous system
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6291511B1 (en) * 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Also Published As

Publication number Publication date
CA2466701C (en) 2013-11-12
WO2003041655A2 (en) 2003-05-22
WO2003041655A3 (en) 2004-09-10
CA2466701A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
AUPR638101A0 (en) Composition and method for treatment of disease
AU2002306768A1 (en) Expression profiles and methods of use
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2002314466A1 (en) Withasol and methods of use
AU2002250331A1 (en) 7-pyrollyl tetracycline compounds and methods of use thereof
AU6118001A (en) Combination therapeutic compositions and methods of use
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2002255752A1 (en) 9-aminoacyl tetracycline compounds and methods of use thereof
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002350079A1 (en) Gel composition and methods of use
IL160835A0 (en) Catheter and method of using same
AU2003260241A1 (en) Buguzhi agent and composition and methods of preparing and administering the same
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002363800A1 (en) Therapeutic agent composition and method of use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
EP1578348A3 (en) Formulation comprising bioactive agents and method of using same
AU2003282593A1 (en) Polyphenolamine composition and method of use
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU2001226609A1 (en) Method and formulation for treatment of vasoconstriction

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase